罗马尼亚慢性淋巴细胞白血病患者的 HLA 基因多态性。

HLA Gene Polymorphisms in Romanian Patients with Chronic Lymphocytic Leukemia.

机构信息

Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, Bucharest 022328, Romania.

Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 258 Fundeni Avenue, Bucharest 022328, Romania.

出版信息

Genet Res (Camb). 2024 Feb 28;2024:8852876. doi: 10.1155/2024/8852876. eCollection 2024.

DOI:10.1155/2024/8852876

PMID:38449839

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10917483/

Abstract

MATERIALS AND METHODS

This study included 66 patients with CLL, diagnosed between 2020 and 2022, and 100 healthy controls. HLA class I and class II genes (HLA-A/B/C, HLA-DQA1/DQB1/DPA1/DPB1, and HLA-DRB1/3/4/5) were investigated using next-generation sequencing technology.

RESULTS

Several HLA alleles were strongly associated with CLL. The most important finding was that HLA-DRB104:02:01 (=0.001, OR = 1.05) and HLA-DRB302:01:01 (=0.009, OR = 1.03) have a predisposing role in CLL development. Moreover, we identified that HLA-A24:02:01 0.01 (=0.01, OR = 0.38), HLA-DQA105:05:01 (=0.01, OR = 0.56), HLA-DQB103:02:01 (=0.03, OR = 0.40), and HLA-DRB401:03:01 (=0.03, OR = 0.54 alleles have protective roles. Correlations between HLA expression and gender showed that women had a higher expression of protective HLA alleles when compared to men.

CONCLUSIONS

Our data are the first to indicate that in Romanian patients with CLL, the HLA-A24:02:01 and HLA-DQA105:05:01 alleles have a protective role against CLL development, whereas HLA-DRB104:02:01 and HLA-DRB302:01:01alleles are positively associated with CLL.

摘要

材料和方法

本研究纳入了 66 例 2020 年至 2022 年间诊断为 CLL 的患者和 100 例健康对照者。采用下一代测序技术检测 HLA Ⅰ类和Ⅱ类基因（HLA-A/B/C、HLA-DQA1/DQB1/DPA1/DPB1 和 HLA-DRB1/3/4/5）。

结果

一些 HLA 等位基因与 CLL 强烈相关。最重要的发现是 HLA-DRB104:02:01（=0.001，OR=1.05）和 HLA-DRB302:01:01（=0.009，OR=1.03）等位基因在 CLL 发病中具有易感性。此外，我们发现 HLA-A24:02:01 0.01（=0.01，OR=0.38）、HLA-DQA105:05:01（=0.01，OR=0.56）、HLA-DQB103:02:01（=0.03，OR=0.40）和 HLA-DRB401:03:01（=0.03，OR=0.54）等位基因具有保护性作用。HLA 表达与性别之间的相关性表明，与男性相比，女性具有更高表达的保护性 HLA 等位基因。